Table 7.6g

Immunosuppression Use for Maintenance Between Discharge

and One Year Following Transplantation, 1994 to 2003

Recipients with Pancreas After Kidney (PAK) Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 54 67 113 130 157 221 303 307 377 343
Tx with Follow-up Immunosuppression Info 37 41 71 89 111 168 218 247 274 256
Corticosteroids Any in Category 21.6% 87.8% 100.0% 100.0% 100.0% 100.0% 99.1% 98.8% 94.2% 78.5%
Steroids 21.6% 87.8% 100.0% 100.0% 100.0% 100.0% 99.1% 98.8% 94.2% 78.5%
Cyclosporine Any in Category 75.7% 68.3% 45.1% 21.3% 32.4% 14.3% 16.1% 15.4% 15.3% 10.9%
Cyclosporin 75.7% 29.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sandimmmune 0.0% 9.8% 7.0% 4.5% 4.5% 2.4% 3.2% 0.8% 1.1% 0.0%
Neoral 0.0% 29.3% 38.0% 16.9% 27.9% 11.9% 11.9% 13.0% 12.0% 9.0%
Gengraf 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9% 0.8% 2.2% 1.6%
Eon 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.8% 0.0% 0.4%
Tacrolimus Any in Category 45.9% 51.2% 67.6% 88.8% 76.6% 91.1% 91.7% 91.9% 87.2% 82.8%
Tacrolimus 45.9% 51.2% 67.6% 88.8% 76.6% 91.1% 91.7% 91.9% 87.2% 82.8%
Antimetabolites Any in Category 94.6% 97.6% 100.0% 100.0% 99.1% 95.2% 84.4% 80.2% 80.3% 84.8%
Mycophenolate Mofetil 0.0% 31.7% 83.1% 89.9% 89.2% 86.3% 78.4% 77.7% 78.1% 80.9%
Azathioprine 94.6% 65.9% 16.9% 10.1% 9.9% 8.9% 6.0% 2.4% 2.2% 3.5%
Leflunomide 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.4%
Cytoxan 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
mTOR Inhibitors Any in Category 0.0% 0.0% 0.0% 0.0% 0.9% 7.1% 24.8% 30.8% 31.8% 27.3%
Sirolimus 0.0% 0.0% 0.0% 0.0% 0.9% 7.1% 24.8% 30.8% 31.8% 27.3%
Everolimus 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 2, 2005.

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug withinthe same category.